AUROBINDO PHARMA LTD.

Aurobindo Pharma Ltd announced the incorporation of its new wholly owned subsidiary, Avogent Lifesciences Private Limited, through its existing subsidiary Apitoria Pharma Private Limited. The new entity, established in India with an initial share capital of ₹5 crore, aims to undertake manufacturing and marketing operations both domestically and internationally. This move is part of Aurobindo's strategic expansion in the pharmaceutical sector. No governmental or regulatory approvals were required for this incorporation, and it is considered a related party transaction as per SEBI regulations.

Aurobindo Pharma announced that its wholly owned subsidiary, Lannett Company LLC, has launched the generic equivalent of Advair Diskus® (fluticasone propionate and salmeterol inhalation powder) in the US market. This marks the first product from Aurobindo's inhalation pipeline to be commercialized in the US. The product is available in 100/50 mcg and 250/50 mcg strengths and is indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). This launch signifies Aurobindo's strategic focus on expanding its complex and differentiated inhalation product portfolio.

Aurobindo Pharma Ltd has announced the completion of a US FDA inspection at Unit-VI of its wholly-owned subsidiary, Apitoria Pharma Private Limited. The inspection, which took place from August 24 to August 28, 2026, at the API manufacturing facility in Andhra Pradesh, concluded with three procedural observations. The company stated it will respond to the US FDA within the stipulated timeline and is committed to maintaining high quality and compliance standards. Further developments will be communicated as required.

Aurobindo Pharma Ltd has announced the completion of a routine US FDA inspection at its wholly owned step-down subsidiary, Lannett Company LLC, located in Seymour, IN, USA. The inspection took place from August 17th to 21st, 2026. The facility concluded the inspection with four observations, which Aurobindo Pharma has stated are procedural in nature. The company will submit its response to the US FDA within the stipulated timeline and remains committed to maintaining high quality and compliance standards across its manufacturing operations. Further developments will be communicated as required.

Aurobindo Pharma announced that its subsidiary, Auro Peptides Limited, has successfully completed a routine inspection by the United States Food and Drug Administration (US FDA). The inspection, which took place from August 17th to 21st, 2026, at the peptide API manufacturing facility in Telangana, concluded with a single observation related to facility and equipment maintenance. Importantly, this observation does not concern data integrity or GMP compliance. Corrective actions were initiated during the inspection, and a formal response will be submitted within the stipulated timeline. This outcome underscores Aurobindo Pharma's commitment to high quality and compliance standards across its operations.

Aurobindo Pharma Ltd announced that its wholly-owned step-down subsidiary, Aurolife Pharma LLC, has received an Establishment Inspection Report (EIR) from the USFDA for its Raleigh Plant in North Carolina. The inspection, conducted from March 24 to April 10, 2025, resulted in 11 observations but has been classified as Voluntary Action Indicated (VAI). This classification means the USFDA has closed the inspection and pending applications for multiple inhalers and other dosage forms manufactured at this facility can now proceed through the USFDA's review process.

Aurobindo Pharma Ltd. announced that its wholly-owned subsidiary, Eugia Pharma Specialities Limited, has received a Warning Letter from the US FDA for its Unit 1 facility. This follows an Official Action Indicated (OAI) status previously received by the unit. The company stated that there will be no impact on existing supplies to the US market. Unit 1 contributes approximately 2% to the company's overall group revenue. Aurobindo Pharma is committed to working with the US FDA and enhancing its compliance.

Aurobindo Pharma Ltd has announced the incorporation of a new wholly owned subsidiary, 'Auropharm Overseas Limited', in India. The subsidiary was incorporated on August 13, 2026, with an initial share capital subscription of ₹10,00,000 in cash. Auropharm Overseas Limited is established to undertake manufacturing and marketing operations both domestically and internationally. This move signifies Aurobindo Pharma's strategic expansion into new operational territories.

Aurobindo Pharma announced its consolidated financial results for the first quarter ended June 30, 2026, reporting a 16.3% year-on-year increase in Revenue from Operations to INR 9,150 Cr. The company saw significant growth across its businesses, with US revenue up 8.1% to INR 3,770 Cr and Europe revenue up 25.6% to INR 2,937 Cr. Growth Markets also performed strongly, with a 37.7% YoY increase to INR 1,063 Cr. Net Profit for the quarter stood at INR 1,032 Cr, a 25.2% increase YoY. The company highlighted a strong net cash position and generated free cash flow of USD 98 million during the quarter. Aurobindo Pharma also received final approval for 10 products from the USFDA.

Aurobindo Pharma Ltd's Board of Directors has approved a proposal to merge two step-down wholly owned subsidiaries, Eugia Steriles Private Limited and Eugia SEZ Private Limited, with Eugia Pharma Specialities Limited, a wholly owned subsidiary. The merger aims to simplify the group structure, eliminate corporate overheads, reduce costs, and improve treasury management and synergy benefits. All three entities are involved in the manufacturing of injectable pharmaceutical products. The transaction is between wholly owned subsidiaries and does not involve any cash consideration or change in the listed entity's shareholding pattern. The combined turnover for FY26 of the three entities was approximately ₹32,196 million.